boston scientific corp (BSX) Key Developments
Boston Scientific Announces CE Mark Approval and First Implants of its Next-Generation X4 Quadripolar CRT-D Systems
Dec 17 13
Boston Scientific Corporation has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN(TM) X4, DYNAGEN(TM) X4, and INOGEN(TM) X4 cardiac resynchronization therapy defibrillators (CRT-Ds), a suite of ACUITY(TM) X4 quadripolar LV leads and the ACUITY(TM) PRO lead delivery system. The ACUITY X4 suite of quadripolar LV leads are designed with multiple electrode spacing configurations to accommodate individual patient anatomy, including 3D spiral designs to maximize electrode contact with the myocardium and minimize pacing capture thresholds in non-apical locations. These leads also feature multiple fixation options to optimize stability and the industry's smallest lead tip to enable physicians to access vessels unavailable to other quadripolar leads. The X4 line of quadripolar CRT-Ds offers large number of pacing vector options in the industry and helps physicians effectively address high-pacing capture thresholds and phrenic nerve stimulation, a common complication of CRT therapy due to close proximity of the phrenic nerve to the desired pacing location in the left ventricle. The X4 CRT-Ds also feature Boston Scientific's six-year warranty and industry-leading longevity. An independent, single-center, observational study of 646 CRT-D recipients (n= 173 BSX, 416 MDT, 57 SJM devices) implanted between January 1, 2008 and December 31, 2010 recently published in the United States showed that during 2.7+/-1.5 years follow-up, only 4% of Boston Scientific device batteries had depleted, compared to 7% from St. Jude Medical and 25% from Medtronic.[iii] X4 CRT-Ds utilize the same, industry-leading battery capacity and advanced battery chemistry as the Boston Scientific devices used in this study.
Boston Scientific Elects David Roux as Board of Director
Dec 16 13
The Board of Directors of Boston Scientific Corporation has elected David Roux as a Director. The appointment of Mr. Roux will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from ten to eleven. The increase in the number of directors and Mr. Roux's appointment to the Board are both effective January 1, 2014. Mr. Roux is a co-founder and Senior Director of Silver Lake, a private equity firm focused on technology investing. Mr. Roux serves on the boards of directors of The National Audubon Society and The Institute for Health Metrics and Evaluation at the University of Washington and the boards of trustees of The Jackson Laboratory and Bowdoin College.
Boston Scientific Corporation Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 08:30 AM
Nov 22 13
Boston Scientific Corporation Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 08:30 AM. Venue: The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022, United States. Speakers: Daniel J. Brennan, Senior Vice President and Corporate Controller, Michael F. Mahoney, Chief Executive Officer, President and Director.
Boston Scientific Corporation Appoints Susan (Susie) Vissers Lisa as Vice President, Investor Relations
Nov 21 13
Boston Scientific Corporation announced the appointment of Susan (Susie) Vissers Lisa as vice president, Investor Relations, effective December 2, 2013. Lisa previously served as senior director, investor relations and corporate development at Abiomed Inc.
Boston Scientific Receives FDA Clearance and CE Mark Approval for Direxion(TM) Torqueable Microcatheter
Nov 19 13
Boston Scientific Corporation has received U.S. Food and Drug Administration clearance and CE Mark approval for its Direxion(TM) Torqueable Microcatheter. Peripheral embolization is a technique used primarily by interventional radiologists to treat liver cancer, uterine fibroids and other challenging conditions. It involves deliberately blocking a blood vessel to prevent blood flow to an area of the body, which can effectively shrink a tumor or block an aneurysm. The Direxion Torqueable Microcatheter is designed to facilitate selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature. The product, offered in either a 0.021" or 0.027" inner diameter microcatheter, features a slotted, nitinol hypotube technology. This technology is designed to maximize torque transmission in the catheter shaft, giving the Direxion Torqueable Microcatheter the best-in-class handling physicians need in order to reach the most challenging anatomy.